An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tivdak

Chemical Nametisotumab vedotin-tftv
Dosage FormLyophilized powder (intravenous; 40 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanySeagen Inc.
Approval Year2021

Indication

  • For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivdak (tisotumab vedotin-tftv) Prescribing Information2021Seagen Inc., Bothell, WA
Document TitleYearSource
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.2021The Lancet Oncology
Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer.2020Clinical Cancer Research